European Primary Care Cardiovascular Society
Applying a strategy of low C-PTP and D-dimer <1000 ng/mL or moderate C-PTP and D-dimer <500 ng/mL to rule out PE identified more individuals with low PE risk and reduced use of imaging.
This post-doc analysis of the ENGAGE AF-TIMI 48 trial showed that the effects of edoxaban vs warfarin on ischemic, bleeding and net clinical outcomes were independent of the degree of comorbidities in patients with AF.
AHA 2019 Considering the epidemic of e-cigarette use, particularly among young people, AHA announced substantial investment in research and activities to raise awareness about the risks of vaping.
AHA 2019 Daily colchicine lowered ischemic events, mostly urgent revascularization, in patients with an MI less than 30 days ago, in the COLCOT trial. Colchicine was well-tolerated.
A study using data of millions of patients showed that there are no differences in effectiveness between drug classes when initiating monotherapy for hypertension, with the exception of lower risk of MI, HHF and stroke with thiazide or thiazide-like diuretics when compared to ACEi.
EPCCS 2019 Monika Hollander asks Peter van der Meer how comorbidities like renal dysfunction and cancer treatment affects management of patients with HF: what is known about treatment in patients with these comorbidities?
This review comprehensively summarizes both preclinical and clinical data on the CV effects of e-cigarette use. CV effects of e-cigarette constituents as well as of e-cigarette exposure are reviewed. With poll
A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Poland.
A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Ukraine.
A brief impression of how EPCCS activities and plans can be useful for primary care physicians in Turkey.
A study of real-world data of 4 large European primary care databases demonstrates that NAFLD is not associated with increased risk of AMI and stroke, after correction for traditional risk factors.
A randomized clinical trial of hypertensive patients demonstrates that ingestion of hypertension medication at bedtime reduces asleep ABP and CVD event risk compared to ingestion upon awakening.
